- Protalix BioTherapeutics demonstrates exceptional capital efficiency, with its Return on Invested Capital (ROIC) significantly exceeding its Weighted Average Cost of Capital (WACC).
- The company boasts an ROIC of 23.33% against a WACC of 6.07%, resulting in an impressive ROIC to WACC ratio of 3.85.
- Unlike many of its industry peers, Protalix BioTherapeutics has achieved profitability, showcasing a more mature financial position compared to competitors still in value-destruction phases.
Protalix BioTherapeutics, Inc. (AMEX: PLX) is a biopharmaceutical firm developing therapeutic proteins with its ProCellEx platform. Its products include Elelyso and Elfabrio. Protalix BioTherapeutics operates in a competitive sector where many companies are still focused on research and development without significant revenue.
A company's health can be measured by comparing its Return on Invested Capital (ROIC) to its Weighted Average Cost of Capital (WACC). ROIC shows how well a company profits from its investments. WACC is the average cost of funding those investments. A company creates value when ROIC is higher than WACC.
Protalix BioTherapeutics demonstrates remarkable capital efficiency. It has an ROIC of 23.33%, which is significantly higher than its WACC of 6.07%. This gives it an ROIC to WACC ratio of 3.85, meaning it generates a return of $3.85 for every dollar of capital it uses.
In stark contrast, Protalix BioTherapeutics's peers are not generating positive returns. Ardelyx, Inc. (NASDAQ: ARDX) has an ROIC of -7.96%, while BioLineRx Ltd. (NASDAQ: BLRX) has an ROIC of -49.89%. Other peers like Pulmatrix, Inc. (NASDAQ: PULM) and Can-Fite BioPharma Ltd. (NYSE American: CANF) also have deeply negative ROIC values.
This negative performance is common for companies investing heavily in clinical trials. However, Protalix BioTherapeutics's positive ROIC to WACC ratio of 3.85 makes it a standout leader. It has successfully crossed into profitability, showing a more mature financial position than its peers who are still in a value-destruction phase.
